CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors. CRB-601 antitumor activity correlated to increased αvβ8 RO and downregulation of TGFβ signaling. Investigational New Drug (IND) enabling studies are in progress.
almost 2 years ago
Immune cell
|
IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)